Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

BACKGROUND: Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit proliferation of melanoma cell lines, we undertook a study to assess the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajewski, Thomas F, Salama, April KS, Niedzwiecki, Donna, Johnson, Jeffrey, Linette, Gerald, Bucher, Cynthia, Blaskovich, Michelle A, Sebti, Said M, Haluska, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543225/
https://www.ncbi.nlm.nih.gov/pubmed/23228035
http://dx.doi.org/10.1186/1479-5876-10-246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543225/
https://www.ncbi.nlm.nih.gov/pubmed/23228035
http://dx.doi.org/10.1186/1479-5876-10-246

Ejemplares similares